In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.
Researchers reported that a two-drug combination of the integrase inhibitor dolutegravir (Tivicay) with the NRTI lamivudine (Epivir) produced a sustained reduction in viral loads to less than 50 copies in 18 out of 20 people.
On behalf of IFARA, Fred Schaich spoke with Pedro Cahn, M.D., Ph.D., about two late-breaking studies presented at this year's International AIDS Conference and about global funding for HIV.
An antiretroviral regimen consisting of just two drugs -- dolutegravir and lamivudine -- led to sustained viral suppression for most people starting HIV treatment for the first time, according to findings from a small study presented in a late-breake...
Dual Therapy With Dolutegravir + 3TC Keep Viral Load Undetectable: 48-Week Results From PADDLE Study
Updated results from the PADDLE study are encouraging for the likelihood of dolutegravir + 3TC (lamivudine) being a durable option.
Dolutegravir-based ART was superior to a boosted atazanavir-based regimen in treatment naive women at 48 weeks, according to data from the ARIA study presented at AIDS 2016.
On behalf of IFARA, Fred Schaich spoke with Kimberly Smith of ViiV Healthcare at this year's International AIDS Conference about 48-week data from the ARIA study of drug efficacy in women with HIV.